

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

BioMark Diagnostics Inc. (“the Issuer”)
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8

Item 2: Date of Material Change

November 26, 2014

Item 3: News Release

A news release was issued and disseminated on November 26, 2014 and filed on SEDAR (www.sedar.com). A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

BioMark Diagnostics Inc. (“BioMark”) announces that it has listed its common shares on the Frankfurt Stock Exchange (FSE) under the ticker symbol 20B, with an international securities identification number (ISIN) of CA09073K1084.

The Frankfurt Stock Exchange is the world’s third largest organized exchange-trading market as measured by trading volume. Only the Nasdaq and the New York Stock Exchanges are larger. BioMark’s shares continue to trade on the Canadian Securities Exchange as the primary market.

Item 5: Full Description of Material Change

Please see the attached Schedule “A”.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Note applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

Rashid Ahmed Bux, President & CEO
Telephone: 604.282.6567
Email: info@biomarkdiagnostics.com

Item 9: Date of Report

November 26, 2014

Schedule "A"



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK LISTS ON FRANKFURT STOCK EXCHANGE

Vancouver, British Columbia – (November 26th, 2014) –BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B) is pleased to announce that it has listed its common shares on the Frankfurt Stock Exchange (FSE) under the ticker symbol 20B, with an international securities identification number (ISIN) of CA09073K1084.

The Frankfurt Stock Exchange is the world's third largest organized exchange-trading market as measured by trading volume. Only the Nasdaq and the New York Stock Exchanges are larger. BioMark's shares continue to trade on the Canadian Securities Exchange as the primary market.

Rashid Ahmed, Chief Executive Officer, said: "This European listing will help to increase Biomark's trading visibility and assist in facilitating investment into the company by European investors."

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.